Cat. No. 4382
Alternative Name: CGS 20267
Chemical Name: 4,4'-(1H-1,2,4-Triazol-1-ylmethylene
Biological ActivityPotent, reversible non-steroidal aromatase inhibitor (IC50 = 11.5 nM). Displays antitumor effects in several animal models. Suppresses the endogenous aromatase-induced proliferation of MCF-7 cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Bhatnagar (2007) The discovery and mechanism of action of letrozole. Breast Cancer Res.Treat. 105 7. PMID: 17912633.
Mitropoulou et al (2003) Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int.J.Cancer 104 155. PMID: 12569569.
Bhatnagar et al (1990) Highly selective inhbition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J.Steroid Biochem.Mol.Biol. 37 1021. PMID: 2149502.
If you know of a relevant reference for Letrozole please let us know.
Citations are publications that use Tocris products. Selected citations for Letrozole include:
Ruiz-Palmero et al (2016) Oestradiol synthesized by female neurons generates sex differences in neuritogenesis. Scientific Reports 6 31891. PMID: 27553191.
Tozzi et al (2015) Endogenous 17β-estradiol is required for activity-dependent long-term potentiation in the striatum: interaction with the dopaminergic system. Front Cell Neurosci 9 192. PMID: 26074768.
Do you know of a great paper that uses Letrozole from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Letrozole, supplier, CGS20267, non-steroidal, aromatase, CYP19, inhibitors, inhibits, potent, reversible, antitumor, antitumour, Tocris Bioscience, Cytochrome P450 Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and highly selective PDE5 inhibitor; orally bioavailable7-Ethoxyresorufin
Fluorometric CYP450 substrateGaleterone
CYP17 inhibitor; also androgen receptor antagonist
September 27 - 30, 2017